Goldman Sachs Group Inc Enanta Pharmaceuticals Inc Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENTA
# of Institutions
110Shares Held
21.1MCall Options Held
4.8KPut Options Held
4.6K-
Farallon Capital Management LLC San Francisco, CA2.11MShares$18.5 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.98MShares$17.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$16.2 Million0.0% of portfolio
-
Krensavage Asset Management, LLC New York, NY1.5MShares$13.1 Million8.7% of portfolio
-
Morgan Stanley New York, NY1.1MShares$9.66 Million0.0% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $182M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...